LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股每股作價226.0879港元

智通財經

05/26

智通財經APP獲悉，香港聯交所最新數據顯示，5月20日，LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股，每股作價226.0879港元，總金額約為2373.92萬港元。增持後最新持股數目約為1175.79萬股，最新持股比例為13.00%。

本交易涉及其他關聯方：施毅。

補充資料：LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2638851904"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638851904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638851904?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-05-26 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638851904","market":"us","top_or_hot":-1,"title":"LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股 每股作價226.0879港元","media":"智通財經","content":"<html><body><p>智通財經APP獲悉，香港聯交所最新數據顯示，5月20日，LAV Asset Management (Hong Kong) Limited增持<a href=\"https://laohu8.com/S/09606\">映恩生物-B</a>(09606)10.5萬股，每股作價226.0879港元，總金額約為2373.92萬港元。增持後最新持股數目約為1175.79萬股，最新持股比例為13.00%。</p><p>本交易涉及其他關聯方：施毅。</p><p>補充資料：LAV <a href=\"https://laohu8.com/S/SGU\">Star</a> Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股 每股作價226.0879港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股 每股作價226.0879港元\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-05-26 19:28</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP獲悉，香港聯交所最新數據顯示，5月20日，LAV Asset Management (Hong Kong) Limited增持<a href=\"https://laohu8.com/S/09606\">映恩生物-B</a>(09606)10.5萬股，每股作價226.0879港元，總金額約為2373.92萬港元。增持後最新持股數目約為1175.79萬股，最新持股比例為13.00%。</p><p>本交易涉及其他關聯方：施毅。</p><p>補充資料：LAV <a href=\"https://laohu8.com/S/SGU\">Star</a> Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1446171.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000500386.USD","symbol_name":"易方達 (香港) 中國股票股息基金A 類 (累積) 美元","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1446171.html","article_id":"2638851904","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638851904","pubTimestamp":1779794912,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP獲悉，香港聯交所最新數據顯示，5月20日，LAV Asset Management  Limited增持映恩生物-B10.5萬股，每股作價226.0879港元，總金額約為2373.92萬港元。增持後最新持股數目約為1175.79萬股，最新持股比例為13.00%。本交易涉及其他關聯方：施毅。補充資料：LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","09606":"映恩生物-B","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","EWH":"香港ETF-iShares MSCI","BK1161":"生物科技","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC"},"translate_title":"LAV Asset Management (Hong Kong) Limited increased its holdings of 105,000 shares of Yingen Bio-B (09606) at HK$226.0879 per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1.5,"09606":1.5},"content_text":"智通財經APP獲悉，香港聯交所最新數據顯示，5月20日，LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股，每股作價226.0879港元，總金額約為2373.92萬港元。增持後最新持股數目約為1175.79萬股，最新持股比例為13.00%。本交易涉及其他關聯方：施毅。補充資料：LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with trade date on May 20, 2026 and settlement date on May 22, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}

LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股 每股作價226.0879港元

熱議股票

LAV Asset Management (Hong Kong) Limited增持映恩生物-B(09606)10.5萬股每股作價226.0879港元